ITMO public health
Last update : 10/19/2015 | Version : 2 | ID : 248
| General | |
| Identification | |
| Detailed name | Registre des patients thalassémiques en France (Registre qualifié) |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL 04-1396 (30/11/2004) |
| General Aspects | |
| Medical area |
Hematology Internal medicine Pediatrics Rare diseases |
| Health determinants |
Genetic |
| Keywords | CohortClinical research |
| Scientific investigator(s) (Contact) | |
| Name of the director | Badens |
| Surname | Catherine |
| Address | Laboratoire de Génétique Moléculaire, Hôpital d’enfants de la Timone, 13385 Marseille cedex 5 |
| Phone | + 33 (0)4 91 38 77 87 |
| catherine.badens@ap-hm.fr | |
| Unit | Laboratoire de Génétique Moléculaire, Hôpital d’enfants de la Timone |
| Organization | Assistance Publique-Hôpitaux de |
| Collaborations | |
| Funding | |
| Funding status |
Public |
| Details | Le centre de référence Thalassémies, une subvention INVS/INSERM pour 2009, 2010, 2011 et 2012 dans le cadre de la labellisation des registres maladies rares. |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Assistance Publique-Hôpitaux de Marseille |
| Organisation status |
Public |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Morbidity registers |
| Additional information regarding sample selection. |
Cases are identified from the following structures-sources:
- Pediatric, pediatric hematology, hematology and internal medicine departments -Hematopoietic stem cell transplant departments -The 4 neonatal screening laboratories for sickle-cell anemia - French blood centers -Accredited molecular genetics laboratories for diagnosing hemoglobin anomalies Cases are validated by Dr Thuret before entry, with the attending physician being contacted when necessary. |
| Database objective | |
| Main objective |
-Obtain national epidemiological data on the disease, particularly its morbidity and, over the longer term, its mortality, which reflect the quality of overall patient care
-Monitor treatment trends over time - especially the increasing use of orally administered active chelators and the spread of new techniques for evaluating tissue overload by heart and liver MRIs. -Compare conventional treatment results combining transfusions and iron chelation with those obtained from hematopoietic stem cell transplants. -Conduct more basic research projects |
| Inclusion criteria |
Beta-thalassemias (TM) major and intermediate (TI), including HbE/thalassemia composite hereterozygosity and thalassemia patients who have had a HSC transplant.
Diagnosis of a severe form of beta-thalassemia is formally established on the basis of data from a biochemical study of hemoglobin with no real differential diagnosis. Distinguishing between thalassemia major and intermediate requires the combination of 3 consensual criteria: • for TM: Severe anemia indicating the setup of a systematic transfusion routine (at least 8 transfusions/year) before the age of 4. • for TI: Moderate or medium intensity anemia that have no or only occasional need for transfusion. The date and circumstances of the diagnosis are asked for upon inclusion and the characteristics of the transfusion treatment upon inclusion and when each follow-up sheet is completed. Identification of the beta-thalassemia mutations or type of beta 0 or beta + mutation are available in most cases, allowing for a complementary approach - even if the TM or TI diagnosis retains a clinical definition. HbE/thalassemia composite hereterozygosity is of biological definition (biochemical or molecular) and can lead to an intermediate or major form of thalassemia: as a result they are subject to the same classification according to the same clinical criteria (age at diagnosis and transfusion needs). |
| Population type | |
| Age |
Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) |
| Population covered |
Sick population |
| Gender |
Male Woman |
| Geography area |
National |
| Detail of the geography area | France |
| Data collection | |
| Dates | |
| Date of first collection (YYYY or MM/YYYY) | 2005 |
| Size of the database | |
| Size of the database (number of individuals) |
[500-1000[ individuals |
| Details of the number of individuals | 287 (2008)479 (2010)515 (2012) |
| Data | |
| Database activity |
Current data collection |
| Type of data collected |
Clinical data Biological data |
| Clinical data (detail) |
Direct physical measures |
| Biological data (detail) | examination of the medical record |
| Presence of a biobank |
Yes |
| Contents of biobank |
Cell lines DNA |
| Details of biobank content | We offer to store a DNA sample, and possibly a cell line for each patient included in the registry, at the biological resource center (CRB) in Marseilles. There are currently some one hundred samples stored in this collection. |
| Health parameters studied |
Health event/morbidity Health event/mortality Others |
| Other (detail) | Professional activities or schooling |
| Procedures | |
| Data collection method | Inclusion or follow-up sheet posted by standard delivery to Marseilles. The data is then entered into the database before being validated. |
| Participant monitoring |
Yes |
| Details on monitoring of participants | A follow-up sheet comprising the same items as the inclusion sheet, along with noting down of the patient's death when it arises and cause of death, is sent to clinicians every 18 months. |
| Links to administrative sources |
No |
| Promotion and access | |
| Promotion | |
| Link to the document | http://www.chu-lyon.fr/web/2652 |
| Link to the document | http://www.haematologica.org/cgi/content/full/95/5/724 |
| Link to the document | http://tinyurl.com/PUBMED-RPT |
| Description | Liste des publications dans Pubmed |
| Access | |
| Terms of data access (charter for data provision, format of data, availability delay) |
Results access procedure: Publications and scientific communications at conferences
Data access procedure for external teams: a request must be submitted to the registry manager (C. Badens) and to the 2 coordinators of the Thalassemia reference center (I. Thuret and C. Pondarré). Acceptance criteria currently being defined. |
| Access to aggregated data |
Access on specific project only |
| Access to individual data |
Access on specific project only |
| ABOUT | CATALOG | RESOURCES | USEFUL LINKS |
This site complies with the HONcode standard for trustworthy health information: |
8 rue de la Croix Jarry 75013 Paris Phone : +33 1 44 23 67 47 |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05
